Inlyta is an FDA-approved anti-cancer drug owned by Pf Prism Cv. The prescription drug, first authorized for market use on January 27, 2012, is available in oral tablet forms and contains the active ingredient axitinib.
The generic version of Inlyta is anticipated to be released after January 12, 2037, marking the expiry date of its last patent, patent number US10869924 titled 'PD-L1 antagonist combination treatments'. The release of the Inlyta generic version will significantly broaden access to this life-saving treatment.
Inlyta is utilized for the first-line treatment of patients with advanced renal cell carcinoma. Its active ingredient, axitinib, enables it to be used in combination with other drugs like Avelumab and Pembrolizumab, enhancing its effectiveness in combating cancer.
Inlyta's protection is under a total of 4 patents, the last of which, 'PD-L1 antagonist combination treatments', will expire on January 12, 2037. The release of the Inlyta generic version is thus projected to occur after this date. Below are the details of the patents: